[
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For June 2025",
    "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
    "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748384108,
      "headline": "Best Dividend Aristocrats For June 2025",
      "id": 134736842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173105185/image_2173105185.jpg?io=getty-c-w1536",
      "related": "MDT",
      "source": "SeekingAlpha",
      "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
      "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455"
    }
  },
  {
    "ts": null,
    "headline": "BTIG Downgrades Globus Medical (GMED) to Neutral on Spine Business Concerns",
    "summary": "On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following the downgrade. Globus Medical is a medical device company specializing in healthcare solutions primarily for musculoskeletal disorders. In early May, the company reported […]",
    "url": "https://finnhub.io/api/news?id=b9a699a54f38a1786afe5dbf2f4492b340881434a7d4525e8369d35f21babc37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748368361,
      "headline": "BTIG Downgrades Globus Medical (GMED) to Neutral on Spine Business Concerns",
      "id": 134716407,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following the downgrade. Globus Medical is a medical device company specializing in healthcare solutions primarily for musculoskeletal disorders. In early May, the company reported […]",
      "url": "https://finnhub.io/api/news?id=b9a699a54f38a1786afe5dbf2f4492b340881434a7d4525e8369d35f21babc37"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic : receives FDA’s Safer Technologies Program (STeP) designation for its investigational Nellcor™ pulse oximetry technology",
    "summary": "Medtronic, a global leader in healthcare technology, announced today that new Nellcor™ pulse oximetry technology currently in-development has been accepted into the U.S. Food and Drug...",
    "url": "https://finnhub.io/api/news?id=3572890d99f00a0ede4a6983775f3a8d9f4f33f9919c6dab11a4cfe3397fffc8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748357420,
      "headline": "Medtronic : receives FDA’s Safer Technologies Program (STeP) designation for its investigational Nellcor™ pulse oximetry technology",
      "id": 134711630,
      "image": "",
      "related": "MDT",
      "source": "Finnhub",
      "summary": "Medtronic, a global leader in healthcare technology, announced today that new Nellcor™ pulse oximetry technology currently in-development has been accepted into the U.S. Food and Drug...",
      "url": "https://finnhub.io/api/news?id=3572890d99f00a0ede4a6983775f3a8d9f4f33f9919c6dab11a4cfe3397fffc8"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Income Stock Fund Q1 2025 Commentary",
    "summary": "BNY Mellon Income Stock Fund (Class A at NAV) returned 3.11% during the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=daa65f5c3dbc517f6c21c1e66b32a2b50aec8c1b7dc22bd14c2abe6bbb05afde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748340060,
      "headline": "BNY Mellon Income Stock Fund Q1 2025 Commentary",
      "id": 134708851,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1881807987/image_1881807987.jpg?io=getty-c-w1536",
      "related": "MDT",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Income Stock Fund (Class A at NAV) returned 3.11% during the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=daa65f5c3dbc517f6c21c1e66b32a2b50aec8c1b7dc22bd14c2abe6bbb05afde"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Equity Income Fund Q1 2025 Commentary",
    "summary": "BNY Mellon Equity Income Fund (Class A at NAV) returned -3.31% during Q1 2025. In comparison, the fundâs benchmark, the S&P 500 Index), returned -4.27% for the same period.",
    "url": "https://finnhub.io/api/news?id=a583b929f39e3fbef876a3795b1a300acdbc5dc632e065f6a6714fab77b63d39",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748330640,
      "headline": "BNY Mellon Equity Income Fund Q1 2025 Commentary",
      "id": 134707724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2142653674/image_2142653674.jpg?io=getty-c-w1536",
      "related": "MDT",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Equity Income Fund (Class A at NAV) returned -3.31% during Q1 2025. In comparison, the fundâs benchmark, the S&P 500 Index), returned -4.27% for the same period.",
      "url": "https://finnhub.io/api/news?id=a583b929f39e3fbef876a3795b1a300acdbc5dc632e065f6a6714fab77b63d39"
    }
  }
]